Moderna Stock’s Short Squeeze Fades: 3 Key Support Levels to Watch

Moderna (MRNA) jumped nearly 20% after its Science Day event showcasing mRNA applications in cancer and rare diseases, but the rally appears driven by short covering rather than fundamentals. Short interest exceeded 16.5% heading into the event, fueling the squeeze that pushed shares well above technical support.

The stock now trades nearly double the consensus price target of $37, raising valuation concerns. Analysts note that Horizon 2 and 3 pipeline products won't generate revenue until after 2028, leaving current vaccine sales to fund the expanded development programs. The gap between price and analyst expectations creates downside risk as short interest normalizes.

Technical levels now matter more than the pipeline narrative. The stock faces three key support zones: $60, $55, and $52. A break below $60 would signal the squeeze has fully unwound, while failure to hold $52 could trigger a deeper retracement toward the $37 consensus target.